Important shareholder notice: khang & khang llp announces an investigation of claims against davita healthcare partners inc. and strongly encourages investors to contact the firm

Irvine, calif.--(business wire)--khang & khang llp announces that it is investigating claims of potential misrepresentations by davita healthcare partners inc. (“davita” or the “company”) (nyse: dva). the investigation focuses on whether the company and its officers violated securities laws by issuing misleading information to investors. if you purchased shares of davita during the class period, please contact joon m. khang, esquire, of khang & khang, 18101 von karman avenue, 3rd floor, irvine, ca 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com. there has been no class certification in this case. until certification occurs, you are not represented by an attorney. you may choose to take no action and remain a passive class member. on february 11, 2016, the company announced that the u.s. attorney's office for the northern district of texas had sent it a civil investigative demand (cid) concerning a false claims act investigation. according to the allegations, davita submitted false claims to the government for prescription drug reimbursement. when the truth was revealed, shares dropped causing investors harm. if you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact joon m. khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com. this press release may constitute attorney advertising in some jurisdictions.
DVA Ratings Summary
DVA Quant Ranking